2023
Impact of COVID-19 on the gastrointestinal surgical oncology patient population
Bakkila B, Marks V, Kerekes D, Kunstman J, Salem R, Billingsley K, Ahuja N, Laurans M, Olino K, Khan S. Impact of COVID-19 on the gastrointestinal surgical oncology patient population. Heliyon 2023, 9: e18459. PMID: 37534012, PMCID: PMC10391949, DOI: 10.1016/j.heliyon.2023.e18459.Peer-Reviewed Original ResearchGI cancer surgeryPreoperative chemotherapyCancer surgerySurgical careCOVID-19 pandemicCOVID-19Tertiary referral centerOncology patient populationFirst COVID-19 waveGI cancer casesCOVID-19 burdenHigh COVID-19 burdenEmergency surgeryReferral centerCOVID-19 waveOncology visitsGastrointestinal cancerGI cancersPatient populationStudy criteriaCancer careTreatment characteristicsCancer casesCase volumePatients
2021
1470P Oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence
Heumann T, Baretti M, Sugar E, Durhman J, Liden S, Miles T, Lopez-Vidal T, Leatherman J, Sharma A, Ahuja N, Weekes C, O'Dwyer P, Monga D, Binder K, Azad N. 1470P Oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence. Annals Of Oncology 2021, 32: s1087-s1088. DOI: 10.1016/j.annonc.2021.08.797.Peer-Reviewed Original Research
2020
22 Poster Discussion A phase II study of Guadecitabine (G) with Irinotecan (IRI) vs regorafenib or TAS-102 in metastatic colorectal cancer (mCRC) patients (pts)
Lee V, Zahurak M, Cercek A, Verheul H, Lenz H, Jones P, Baylin S, Parkinson R, Rami V, Lilly E, Miles T, Brown T, Ahuja N, Khoueiry A, Azad N. 22 Poster Discussion A phase II study of Guadecitabine (G) with Irinotecan (IRI) vs regorafenib or TAS-102 in metastatic colorectal cancer (mCRC) patients (pts). European Journal Of Cancer 2020, 138: s12. DOI: 10.1016/s0959-8049(20)31096-0.Peer-Reviewed Original ResearchS0101 Clinical and Demographic Predictors of Rapidly Progressive Disease in Patients Undergoing Surgery for Pancreatic Ductal Adenocarcinoma: Risk Profiling From the National Cancer Database
Ilagan-Ying Y, Ying L, Ferrucci L, Peters N, Blackburn H, Kunstman J, Ahuja N. S0101 Clinical and Demographic Predictors of Rapidly Progressive Disease in Patients Undergoing Surgery for Pancreatic Ductal Adenocarcinoma: Risk Profiling From the National Cancer Database. The American Journal Of Gastroenterology 2020, 115: s48-s49. DOI: 10.14309/01.ajg.0000702452.53969.ae.Peer-Reviewed Original ResearchPandemic Recovery Using a COVID-Minimal Cancer Surgery Pathway
Boffa DJ, Judson BL, Billingsley KG, Galetta D, Fontanez P, Odermatt C, Lindner K, Mitchell MR, Henderson CM, Carafeno T, Pinto J, Wagner J, Ancuta M, Beley P, Turner AL, Banack T, Laurans MS, Johnson DC, Yoo P, Morton JM, Zurich H, Davis K, Ahuja N. Pandemic Recovery Using a COVID-Minimal Cancer Surgery Pathway. The Annals Of Thoracic Surgery 2020, 110: 718-724. PMID: 32417195, PMCID: PMC7227551, DOI: 10.1016/j.athoracsur.2020.05.003.Peer-Reviewed Original ResearchConceptsSurgery pathwayHospital-acquired COVID-19 infectionLarge academic medical centerCOVID-19 patientsCoronavirus disease 2019 (COVID-19) pandemicCOVID-19 infectionPatient care pathwayAcademic medical centerDisease 2019 pandemicHealth care deliveryOnly surgerySurgery populationElective surgeryPatient survivalRisk of exposureProtection of patientsCare pathwayNosocomial infectionsMedical CenterCare deliverySurgical activityHospitalPatientsSurgeryMost hospitals
2019
MAPT promoter CpG island hypermethylation is associated with poor prognosis in patients with stage II colorectal cancer
Wang C, Liu Y, Guo W, Zhu X, Ahuja N, Fu T. MAPT promoter CpG island hypermethylation is associated with poor prognosis in patients with stage II colorectal cancer. Cancer Management And Research 2019, 11: 7337-7343. PMID: 31496795, PMCID: PMC6689138, DOI: 10.2147/cmar.s206731.Peer-Reviewed Original ResearchStage II colorectal cancerColorectal cancerFive-year overall survival rateStage II CRC patientsOverall survival rateCox regression analysisImportant prognostic variablesProximal colon tumorsCpG island methylator phenotype (CIMP) statusMicrotubule-associated protein tauCIMP-high tumorsPromoter CpG islandsCRC patientsWorse prognosisPoor prognosisPrognostic valuePrognostic markerPrognostic variablesPatientsHigh tumorSurvival rateAlzheimer's diseaseColon tumorsMultivariate analysisProtein tauEpigenetic priming prior to pembrolizumab in mismatch repair-proficient advanced colorectal cancer.
Murphy A, Walker R, Lutz E, Parkinson R, Ahuja N, Zheng L, Jaffee E, Azad N. Epigenetic priming prior to pembrolizumab in mismatch repair-proficient advanced colorectal cancer. Journal Of Clinical Oncology 2019, 37: 591-591. DOI: 10.1200/jco.2019.37.4_suppl.591.Peer-Reviewed Original ResearchArm BArm AColorectal cancerAdvanced CRC patientsMedian treatment cycleMMR-deficient CRCMMR-proficient tumorsLines of chemotherapyAdvanced colorectal cancerPre-treatment biopsiesPost-treatment biopsiesPredictors of responseEpigenetic therapyCTCAE v4.0CRC patientsImmune checkpointsMedian ageProficient tumorsRepeat biopsySingle institutionDisease progressionArm C.Arm CGrade 3Patients
2018
Extraskeletal versus Skeletal Ewing Sarcoma in the adult population: Controversies in care
Lynch AD, Gani F, Meyer CF, Morris CD, Ahuja N, Johnston FM. Extraskeletal versus Skeletal Ewing Sarcoma in the adult population: Controversies in care. Surgical Oncology 2018, 27: 373-379. PMID: 30217290, DOI: 10.1016/j.suronc.2018.05.016.Peer-Reviewed Original ResearchConceptsExtraskeletal Ewing's sarcomaCharlson-Deyo scoreOverall survivalTriple therapyCombination therapyLocal therapyEwing's sarcomaProportional hazards regression analysisHazards regression analysisSkeletal Ewing sarcomaEwing's sarcoma patientsAdult patientsIndependent predictorsEE patientsSarcoma patientsRisk factorsTreatment characteristicsSmall tumorsOutcome differencesPatientsTherapyAdult populationLack of consensusChemotherapyRegression analysisAutomated diagnosis of colon cancer using hyperspectral sensing
Beaulieu RJ, Goldstein SD, Singh J, Safar B, Banerjee A, Ahuja N. Automated diagnosis of colon cancer using hyperspectral sensing. International Journal Of Medical Robotics And Computer Assisted Surgery 2018, 14: e1897. PMID: 29479794, DOI: 10.1002/rcs.1897.Peer-Reviewed Original ResearchConceptsColorectal cancerPossible metastatic diseaseColorectal cancer detectionColorectal cancer reliesMultiple tumor typesMetastatic diseaseOperative resectionSurgical resectionPathologic evaluationSurgical managementCancer reliesTumor specimensColon specimensColon cancerTumor typesPatient specimensCancerResectionPatientsDiagnostic methodsTumorsCancer detectionDiagnostic technologiesContrast agents
2017
Circulating Epithelial Cells in Intraductal Papillary Mucinous Neoplasms and Cystic Pancreatic Lesions
Poruk KE, Valero V, He J, Ahuja N, Cameron JL, Weiss MJ, Lennon AM, Goggins M, Wood LD, Wolfgang CL. Circulating Epithelial Cells in Intraductal Papillary Mucinous Neoplasms and Cystic Pancreatic Lesions. Pancreas 2017, 46: 943-947. PMID: 28697136, DOI: 10.1097/mpa.0000000000000869.Peer-Reviewed Original ResearchConceptsIntraductal papillary mucinous neoplasmHigh-grade dysplasiaPapillary mucinous neoplasmBlood of patientsEpithelial cellsMucinous neoplasmsPancreatic lesionsAbsence of malignancyBenign pancreatic lesionsCystic pancreatic lesionsNineteen patientsPancreatic resectionPeripheral bloodPancreatic cystsISET methodPatientsPancreas-specific markersResectionMalignancyDysplasiaBloodNeoplasmsPancreatic sourceLow gradeLesionsNeutrophil-to-lymphocyte Ratio is a Predictive Marker for Invasive Malignancy in Intraductal Papillary Mucinous Neoplasms of the Pancreas
Gemenetzis G, Bagante F, Griffin JF, Rezaee N, Javed AA, Manos LL, Lennon AM, Wood LD, Hruban RH, Zheng L, Zaheer A, Fishman EK, Ahuja N, Cameron JL, Weiss MJ, He J, Wolfgang CL. Neutrophil-to-lymphocyte Ratio is a Predictive Marker for Invasive Malignancy in Intraductal Papillary Mucinous Neoplasms of the Pancreas. Annals Of Surgery 2017, 266: 339-345. PMID: 27631774, DOI: 10.1097/sla.0000000000001988.Peer-Reviewed Original ResearchConceptsIntraductal papillary mucinous neoplasmPapillary mucinous neoplasmInvasive carcinomaPredictive nomogramLymphocyte ratioMucinous neoplasmsInvasive malignancyPredictive markerMain pancreatic duct dilatationEnhanced solid componentLymphocyte ratio valuesIndependent predictive markerFurther prospective studiesPancreatic duct dilatationInflammatory markersSurgical resectionDuct dilatationNLR valuesOverall survivalProspective studyPancreatic cancerC-indexCarcinomaMultivariate analysisPatients
2016
Locally advanced primary recto-sigmoid cancers: Improved survival with multivisceral resection
Laurence G, Ahuja V, Bell T, Grim R, Ahuja N. Locally advanced primary recto-sigmoid cancers: Improved survival with multivisceral resection. The American Journal Of Surgery 2016, 214: 432-436. PMID: 28082009, DOI: 10.1016/j.amjsurg.2016.12.018.Peer-Reviewed Original ResearchConceptsMultivisceral resectionAdvanced colorectal cancerColorectal cancerCancer patientsYear survivalNon-metastatic colorectal cancerRadiation treatmentRecto-sigmoid cancerFive-year survivalSignificant associated morbidityKaplan-Meier analysisExtensive surgical proceduresGreatest survival advantageEligible patientsAssociated morbiditySelect patientsMeier analysisStandard surgeryRadical operationSEER dataAdjacent organsSurgical proceduresSurvival advantagePatientsSurgical specialistsGastric and small intestine gastrointestinal stromal tumors: Do outcomes differ?
Giuliano K, Nagarajan N, Canner J, Najafian A, Wolfgang C, Schneider E, Meyer C, Lennon AM, Johnston FM, Ahuja N. Gastric and small intestine gastrointestinal stromal tumors: Do outcomes differ? Journal Of Surgical Oncology 2016, 115: 351-357. PMID: 27885685, DOI: 10.1002/jso.24514.Peer-Reviewed Original ResearchConceptsSmall intestine gastrointestinal stromal tumorGastrointestinal stromal tumorsCause-specific mortalityGIST patientsDiagnosis of GISTCases of GISTLarge nation-wide studyGastric gastrointestinal stromal tumorsGastric GIST patientsCommon mesenchymal tumorsFive-year survivalApproval of imatinibNation-wide studySEER databaseStromal tumorsMesenchymal tumorsGastrointestinal tractAge 50PatientsSurvival analysisSimilar outcomesTumorsPrevious reportsFrequent useOutcomesTumors with unmethylated MLH1 and the CpG island methylator phenotype are associated with a poor prognosis in stage II colorectal cancer patients
Fu T, Liu Y, Li K, Wan W, Pappou EP, Iacobuzio-Donahue CA, Kerner Z, Baylin SB, Wolfgang CL, Ahuja N. Tumors with unmethylated MLH1 and the CpG island methylator phenotype are associated with a poor prognosis in stage II colorectal cancer patients. Oncotarget 2016, 5: 86480-86489. PMID: 27880934, PMCID: PMC5349928, DOI: 10.18632/oncotarget.13441.Peer-Reviewed Original ResearchConceptsDisease-free survivalStage II colorectal cancer patientsStage II CRC patientsCpG island methylator phenotypeMLH1 methylation statusColorectal cancer patientsOverall survivalLymphovascular invasionCRC patientsCancer patientsMucin productionMethylator phenotypeKaplan-Meier analysisPoor clinical outcomeMethylation statusDuodenal adenocarcinomaClinical outcomesAggressive featuresPoor prognosisPrognostic valuePatient subgroupsTumor locationMultivariate analysisPatientsM groupO1-10-3 Associations of IGFBP3 SNPs, methylation and recurrence risk in patients with stage II colorectal cancer
Fu T, Li F, Ye J, Liu Z, Wolfgang C, Iacobuzio-Donahue C, Tong W, Liu B, Ahuja N. O1-10-3 Associations of IGFBP3 SNPs, methylation and recurrence risk in patients with stage II colorectal cancer. Annals Of Oncology 2016, 27: vii78. DOI: 10.1093/annonc/mdw521.016.Peer-Reviewed Original ResearchPredictors of improved survival for patients with retroperitoneal sarcoma
Giuliano K, Nagarajan N, Canner JK, Wolfgang CL, Bivalacqua T, Terezakis S, Herman J, Schneider EB, Ahuja N. Predictors of improved survival for patients with retroperitoneal sarcoma. Surgery 2016, 160: 1628-1635. PMID: 27495850, DOI: 10.1016/j.surg.2016.05.041.Peer-Reviewed Original ResearchConceptsRetroperitoneal sarcomaMultivariable survival analysisSurvival analysisRetroperitoneal sarcoma patientsEnd Results (SEER) databaseOperative resectionImproved survivalLymph nodesSurvival benefitDistant metastasisHistologic typeResults databaseSarcoma patientsRare tumorCancer DatabaseLonger survivalPatientsSarcomaSurvivalParametric survival functionsLocal extensionFurther studiesHigh rateResectionRecurrenceA Contemporary Evaluation of the Cause of Death and Long‐Term Quality of Life After Total Pancreatectomy
Wu W, Dodson R, Makary MA, Weiss MJ, Hirose K, Cameron JL, Ahuja N, Pawlik TM, Wolfgang CL, He J. A Contemporary Evaluation of the Cause of Death and Long‐Term Quality of Life After Total Pancreatectomy. World Journal Of Surgery 2016, 40: 2513-2518. PMID: 27177647, DOI: 10.1007/s00268-016-3552-8.Peer-Reviewed Original ResearchConceptsCause of deathTotal pancreatectomyInsulin-dependent diabetesDiabetes-dependent QoLSF-36 surveyShort Form-36Majority of deathsLong-term qualityTotal hospitalizationsForm-36Preoperative stateDiabetes complicationsPreoperative assessmentWorse QoLDiabetic complicationsQOL surveyDiffuse diseasePatientsPancreatic enzymesQoLEuropean OrganizationHealth changesLife implicationsDeathPancreatectomyIGFBP-3 Gene Methylation in Primary Tumor Predicts Recurrence of Stage II Colorectal Cancers
Fu T, Pappou EP, Guzzetta AA, de Freitas Calmon M, Sun L, Herrera A, Li F, Wolfgang CL, Baylin SB, Iacobuzio-Donahue CA, Tong W, Ahuja N. IGFBP-3 Gene Methylation in Primary Tumor Predicts Recurrence of Stage II Colorectal Cancers. Annals Of Surgery 2016, 263: 337-344. PMID: 25822686, PMCID: PMC4648704, DOI: 10.1097/sla.0000000000001204.Peer-Reviewed Original ResearchConceptsStage II colorectal cancerRisk of recurrenceIGFBP-3 methylationLymph nodesColorectal cancerHazard ratioPrimary tumorHigh riskIndependent cohortFive-year recurrence-free survival ratesRecurrence-free survival ratesHigh-risk patientsSignificant prognostic factorsIdentification of patientsProportional hazards modelIGFBP-3Prognostic factorsTumor characteristicsPredicts RecurrenceHazards modelPatientsRecurrenceSurvival rateMultivariate analysisSurgery
2015
Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma
Rezaee N, Barbon C, Zaki A, He J, Salman B, Hruban RH, Cameron JL, Herman JM, Ahuja N, Lennon AM, Weiss MJ, Wood LD, Wolfgang CL. Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma. Hepato Pancreato Biliary 2015, 18: 236-246. PMID: 27017163, PMCID: PMC4814593, DOI: 10.1016/j.hpb.2015.10.010.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Pancreatic DuctalDatabases, FactualDisease-Free SurvivalFemaleHumansKaplan-Meier EstimateLymphatic MetastasisMaleMiddle AgedNeoplasm GradingNeoplasm InvasivenessNeoplasms, Cystic, Mucinous, and SerousNeoplasms, Second PrimaryPancreatectomyPancreatic NeoplasmsProportional Hazards ModelsRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeConceptsIntraductal papillary mucinous neoplasmHigh-grade dysplasiaPancreatic ductal adenocarcinomaNon-invasive intraductal papillary mucinous neoplasmsIntermediate-grade dysplasiaPapillary mucinous neoplasmRemnant pancreasVascular invasionMucinous neoplasmsDuctal adenocarcinomaInvasive pancreatic ductal adenocarcinomaMedian overall survivalLymph node metastasisRate of progressionSubsequent developmentIntermediate dysplasiaPancreatic resectionOverall survivalNode metastasisPerineural invasionMalignant entitiesRisk factorsPatientsDysplasiaPancreasEarly outcomes after elective colorectal surgery in end stage renal disease (ESRD) vs non-ESRD Patients
Arhuidese I, Malas M, Obeid T, Qazi U, Ahuja N, Efron J. Early outcomes after elective colorectal surgery in end stage renal disease (ESRD) vs non-ESRD Patients. Journal Of The American College Of Surgeons 2015, 221: e59. DOI: 10.1016/j.jamcollsurg.2015.08.052.Peer-Reviewed Original Research